Literature DB >> 2167930

Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.

H J Geerligs1, C H Kocken, J W Drijfhout, W J Weijer, W Bloemhoff, J B Wilterdink, G W Welling, S Welling-Wester.   

Abstract

Mice were immunized with synthetic peptides covering the first 56 amino acids of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) and a fusion protein, produced in Escherichia coli, containing the first 55 amino acid residues of gD. It was found that mice immunized with peptides composed of amino acid residues 1 to 13, 18 to 30. 22 to 38 and 38 to 56 of gD were not significantly protected against a lethal challenge with HSV-1. Immunization with peptide 9-21 and the gD fusion protein resulted in significant protection. Antisera, from mice immunized with HSV-1, were investigated for reactivity with a series of 57 overlapping gD peptides covering the entire amino acid sequence, except for the membrane-spanning region. All antisera reacted with peptides 9-21, 10-24, 151-165, 216-232, 282-301 and with peptide 340-354 located in the anchoring region of gD, and 15 other peptides were recognized by at least one antiserum. Twelve peptides (10-24, 151-165, 216-232, 244-267, 260-274, 270-284, 260-284, 282-301, 300-314, 340-354, 348-362 and 355-369) reacted most frequently with the hyperimmune sera from mice and were selected for further study. These were conjugated to bovine serum albumin and used to immunize rabbits. Only antisera against peptide 10-24, which covers the same epitope as peptide 9-21, neutralized HSV-1 in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167930     DOI: 10.1099/0022-1317-71-8-1767

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Analogues of peptide 9-21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies.

Authors:  S Welling-Wester; M Feijlbrief; D G Koedijk; J W Drijfhout; W J Weijer; A J Scheffer; G W Welling
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

3.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

4.  T cell responses to synthetic peptides of herpes simplex virus type 1 glycoprotein D in naturally infected individuals.

Authors:  R A Damhof; J W Drijfhout; A J Scheffer; J B Wilterdink; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

5.  Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.

Authors:  Xingsheng Wang; Guangyan Xie; Jianming Liao; Dengke Yin; Wenyan Guan; Mingjie Pan; Jingnian Li; Yuexi Li
Journal:  Virol J       Date:  2011-05-16       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.